CN101375847A - Medicament composition with dehydration and diuresis functions - Google Patents
Medicament composition with dehydration and diuresis functions Download PDFInfo
- Publication number
- CN101375847A CN101375847A CNA2008100302307A CN200810030230A CN101375847A CN 101375847 A CN101375847 A CN 101375847A CN A2008100302307 A CNA2008100302307 A CN A2008100302307A CN 200810030230 A CN200810030230 A CN 200810030230A CN 101375847 A CN101375847 A CN 101375847A
- Authority
- CN
- China
- Prior art keywords
- piracetam
- dehydration
- mannitol
- pharmaceutical composition
- diuresis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A pharmaceutical combination with the dehydration diuretic effect contains: 5-15 parts of mannitol, 5-15 parts of piracetam and 100 parts of pharmaceutically acceptable carrier according to parts by weight. The pharmaceutical combination has the advantages of fewer side effects, cheap price and the like.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly a kind of pharmaceutical composition with dehydration and diuresis functions.
Background technology
At cerebral trauma, cerebral hemorrhage, cerebral infarction, meningitis, the cerebral tumor, carbon monoxide poisoning, glaucoma etc. behind the sick and wounded and cerebral surgery operation, the patient is because intracranial pressure rising or intraocular pressure rising in various degree can appear in brain essence edema or occupying lesion, rehabilitation of patients and treatment there are significant impact, must do treatment timely and effectively and handle.Tradition is used for the treatment of first-selected 20% formula mannitol injection liquid of medicine of intracranial pressure and intraocular pressure rising.Though the curative effect of 20% formula mannitol injection liquid is certain, because of its ampoule is big, bring serious side effects such as electrolyte disturbance, renal function injury, not only restricted the performance of its curative effect, also caused adverse effect to the patient.In addition, the formula mannitol injection liquid of high concentration is also easily separated out crystallization at low temperatures, uses very inconvenience.
The inventor once disclosed piracetam in the application aspect prevention and the treatment intracranial hypertension at the CN1250651A Chinese invention patent, and disclosed a kind of pharmaceutical composition, and in weight portion, it contains 160 parts of piracetams, 40 parts in mannitol, 1000 parts of waters for injection.Though this kind medicine can avoid the side effect that folk prescription mannitol brings and use in inconvenience, but because of this kind drug regimen system is Main Ingredients and Appearance with the piracetam, mannitol is auxiliary composition, the weight ratio of the two has reached 4, the side effect of piracetam manifests apparent in view, can produce injection site local excitation and pain.In addition, because the piracetam price is higher, part patient can't bear because of economic cause.
Summary of the invention
The problem to be solved in the present invention provides a kind of cheap and pharmaceutical composition that side effect is little, for tissue dewatering and osmotic diuresis, increases in order to prevention and treatment intracranial pressure or intraocular pressure.
For realizing purpose of the present invention, technical scheme provided by the invention is: a kind of pharmaceutical composition with dehydration and diuresis functions is characterized in that: contain by weight: 5-15 part mannitol; 5-15 part piracetam; 100 parts of pharmacy acceptable carriers.
Aforementioned pharmaceutical compositions reduces the consumption of piracetam by adding mannitol, but the amount when the mannitol consumption still is lower than its folk prescription use, it not only can effectively reduce the side effect of using folk prescription mannitol or heavy dose of piracetam to bring, also can reduce cost, alleviate patient and family members' thereof economic pressures.The experiment proved that, the curative effect of aforementioned pharmaceutical compositions is better than folk prescription mannitol, can approach the folk prescription piracetam, can effectively prevent and treat intracranial pressure and intraocular pressure increases, can prevent the crenulation that excessively causes because of dewatering again, thereby the erythrocyte oxygen carrying capacity be reduced and the adverse effect brought to patient body.
Scheme is that the weight ratio of mannitol and piracetam is 3-0.5 preferably.The piracetam consumption is few more, and cost is low more, but crosses low can affecting the treatment, and the side effect meeting of mannitol embodiment is very obvious.Otherwise the consumption of piracetam is big more, and the side effect meeting of mannitol is more little, and curative effect can be good more.But after the consumption of piracetam acquired a certain degree, the consumption of piracetam increased again, and the increase of curative effect will be no longer obvious also, and the side effect meeting of piracetam embodiment clearly, and the cost of compositions also can be higher.
Better scheme is that the weight ratio of mannitol and piracetam is 1, can bring into play the advantage separately of mannitol and piracetam so respectively, overcomes its shortcoming separately, and is not only evident in efficacy, side effect is low, and excellent in stability, cost are lower.
Not bad scheme is when the pharmacy acceptable carrier is deionized water, and the pharmaceutical composition with dehydration and diuresis functions also further comprises 0.8-0.9 part sodium chloride.This moment, pharmaceutical composition existed with the form of injection, can be divided in the glass or plastic infusion bottle of 200 milliliters, 100 milliliters or 50 milliliters, to adapt to the patient of different weight, different severity extents.
Above-mentioned injection is imported to patient with brain trauma fast, can make that patient's intracranial pressure descends, headache, feel sick, sx or disappearance such as vomiting, promote coma patient to revive, reduce generation as sequela such as disorder of limb ' s activity, cognitive competence decline, aphasis.
The quick vein of patient that causes cerebral to increase above-mentioned injection to the cerebral tumor splashes into its cerebral is descended, headache, feel sick, symptoms of emesis alleviates, and keeps medication, can improve the chronic cerebral of patient and increase symptom, improve the quality of living.
Above-mentioned injection is used for acute cerebral infarction, can prevents and treats the cerebral that causes because of cerebral infarction and raise, can alleviate clinical symptoms, promote patients ' recovery, reduce the generation probability of sequela.
Above-mentioned injection is used for by the diuresis dehydration, can reducing intraocular pressure, alleviating symptoms such as patient's headache, visual deterioration because the intraocular pressure due to the eye part diseases such as glaucoma raises.
Above-mentioned injection is used for for the success rate that improves the replantation of amputated limb, reducing amputation because the serious limb swelling that wound causes is eliminated the limbs disturbance of blood circulation that causes because of swelling, the limb preservation function, the protection labour force can produce positive effect.
Above-mentioned injection is used for because the high patient of chronic brain voltage rise that tuberculous meningitis and other encephalitis cause, can alleviates chronic cerebrals such as headache, dizziness, nauseating, vomiting and increase symptom, improve its quality of life and bring into play useful effect.
Below the invention will be further described by specific embodiment.
The specific embodiment
A kind of pharmaceutical composition with dehydration and diuresis functions of the present invention can be made by the following method:
By weight, get: 5-15 part mannitol, 5-15 part piracetam and 0.8-0.9 part sodium chloride are dissolved in 100 parts of deionized waters, filter, and survey semi-finished product content, after the accent pH value is qualified, and packing behind the fine straining, finished product is made in sterilization again.Sterilization can be passed through 100 ℃, 30 minutes steam sterilizations.
The amount of mannitol and piracetam can be adjusted within the specific limits according to patient's body constitution, body weight, severity extent and economic capability etc., table one has exemplified several concrete drug regimen composition formula of the present invention, and wherein mannitol and piracetam content are all inequality in the pharmaceutical composition with dehydration and diuresis functions of embodiment 1 to embodiment 3.
Table one prescription
Comparative Examples
Table two has been enumerated the concrete prescription of several folk prescription piracetams and mannitol.
The prescription of table two Comparative Examples
The contrast experiment
The foregoing description 1 to embodiment 3, Comparative Examples 1 are surveyed the compositions osmotic pressure under the same conditions to Comparative Examples 6, the ratio of calculation composition osmotic pressure/plasma osmotic pressure, concrete outcome sees Table three.Wherein, plasma osmotic pressure is in 290mmol/kg.
The ratio of table three compositions osmotic pressure and plasma osmotic pressure
By compound medicament composition of the present invention and folk prescription piracetam or the folk prescription mannitol suitable with the mannitol total concentration with piracetam are compared, being about to embodiment 1 compares with Comparative Examples 1 and Comparative Examples 4, embodiment 2 compares with Comparative Examples 2 and Comparative Examples 5, embodiment 3 compares with Comparative Examples 3 and Comparative Examples 6, we are not difficult to find that the ratio of osmotic pressure/plasma osmotic pressure that the present invention has a pharmaceutical composition of dehydration and diuresis functions is higher than or a little less than the folk prescription piracetam, is higher than folk prescription mannitol.This explanation, the pharmaceutical composition that the present invention has dehydration and diuresis functions is equivalent to the piracetam of folk prescription, and is better than folk prescription mannitol.But because the consumption of piracetam and mannitol is all low than what use in the prior art, so side effect also greatly reduces.In addition, because the piracetam price is higher, the pharmaceutical composition that the present invention has dehydration and diuresis functions can reduce cost by reducing its consumption, thereby makes the patient can promptly obtain to be equivalent to the curative effect of folk prescription piracetam with lower price.
The pH value stability test
The pharmaceutical composition with dehydration and diuresis functions of embodiment 1 to embodiment 3 is carried out 0-8 hour PH test, and its result as shown in Table 4.
Table four pH value test result
From above result of the test as can be seen, the pH value of embodiment 1 to embodiment 3 did not have significant change in 8 hours, illustrate that the present invention has that the concentration of piracetam and mannitol can not cause tangible influence to pH value in the pharmaceutical composition of dehydration and diuresis functions, its pH value is stable.
The temperature stability test
Pharmaceutical composition with dehydration and diuresis functions and Comparative Examples 1 to the compositions of Comparative Examples 3 of embodiment 1 to embodiment 3 are carried out 10 hours front and back chromatography of high temperature steaming, by chromatogram as can be seen, desolventize outside peak and the piracetam main peak, other peaks do not occur.Table five is listed in embodiment 1 to embodiment 3 before 100 ℃ of high temperature steamings, the Comparative Examples 1 piracetam average peak face amount S0 to Comparative Examples 3, embodiment 1 to embodiment 3, Comparative Examples 1 be to the piracetam average peak face amount S10 of Comparative Examples 3 behind 100 ℃, 10 hours high temperature steamings, and piracetam average peak face amount accounts for the percentage ratio M of piracetam average peak face amount before the steaming and decocting behind the high temperature steaming.
Table five temperature stability result of the test
As can be seen from the above table, the average peak face amount of piracetam does not have significant change before and after the high temperature steaming, illustrate that the concentration of piracetam does not have the significance variation, and the high-temperature stability of pharmaceutical composition that promptly has dehydration and diuresis functions is better.
Piracetam than folk prescription, pharmaceutical composition that the present invention has a dehydration and diuresis functions is behind high temperature steaming, what the content of piracetam reduced still less or slightly increases, and illustrate that temperature has a pharmaceutical composition of dehydration and diuresis functions to the present invention drug effect influences littler.
Describing with reference to some preferred embodiments when of the present invention, persons skilled in the art will recognize that:, may make various modification, variation, omission and replacement not departing under the spiritual principles of the present invention.For example, the amount of piracetam, mannitol is not limited to the scope that provides among the embodiment in the foregoing description; In addition; pharmaceutical composition of the present invention can also be made tablet, oral liquid etc. under the situation that is aided with the carrier that other can pharmacy; perhaps mannitol, piracetam are mixed with injecting fluid mutually with the effective ingredient that other reduces intracranial pressure and intraocular pressure; as long as their obtained effects are identical, these simple variations still belong to protection scope of the present invention.
Claims (4)
1, a kind of pharmaceutical composition with dehydration and diuresis functions is characterized in that: contain by weight:
5-15 part mannitol;
5-15 part piracetam;
100 parts of pharmacy acceptable carriers.
2, according to the described a kind of pharmaceutical composition of claim 1, it is characterized in that with dehydration and diuresis functions:
The weight ratio of described mannitol and described piracetam is 3-0.5.
3, according to the described a kind of pharmaceutical composition of claim 1, it is characterized in that with dehydration and diuresis functions:
The weight ratio of described mannitol and described piracetam is 1.
4, according to each described a kind of pharmaceutical composition of claim 1 to 3, it is characterized in that with dehydration and diuresis functions:
When described pharmacy acceptable carrier was deionized water, described a kind of pharmaceutical composition with dehydration and diuresis functions also further comprised 0.8-0.9 part sodium chloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100302307A CN101375847A (en) | 2008-08-12 | 2008-08-12 | Medicament composition with dehydration and diuresis functions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100302307A CN101375847A (en) | 2008-08-12 | 2008-08-12 | Medicament composition with dehydration and diuresis functions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101375847A true CN101375847A (en) | 2009-03-04 |
Family
ID=40419692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100302307A Pending CN101375847A (en) | 2008-08-12 | 2008-08-12 | Medicament composition with dehydration and diuresis functions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101375847A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657665A (en) * | 2012-04-25 | 2012-09-12 | 和光学 | Compound dehydration and diuresis medicine composition |
| CN104721183A (en) * | 2015-04-09 | 2015-06-24 | 山东罗欣药业集团股份有限公司 | Pharmaceutical composition preparation containing piracetam and preparing method thereof |
| CN113476412A (en) * | 2021-07-02 | 2021-10-08 | 海南通用康力制药有限公司 | Preparation method of piracetam freeze-dried powder injection for injection |
-
2008
- 2008-08-12 CN CNA2008100302307A patent/CN101375847A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657665A (en) * | 2012-04-25 | 2012-09-12 | 和光学 | Compound dehydration and diuresis medicine composition |
| CN102657665B (en) * | 2012-04-25 | 2013-09-11 | 和光学 | Compound dehydration and diuresis medicine composition |
| CN104721183A (en) * | 2015-04-09 | 2015-06-24 | 山东罗欣药业集团股份有限公司 | Pharmaceutical composition preparation containing piracetam and preparing method thereof |
| CN113476412A (en) * | 2021-07-02 | 2021-10-08 | 海南通用康力制药有限公司 | Preparation method of piracetam freeze-dried powder injection for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Finn et al. | Observations on the perioperative management of aneurysmal subarachnoid hemorrhage | |
| CN102008483A (en) | Candesartan-containing compound preparation for treating hypertension | |
| CN101375847A (en) | Medicament composition with dehydration and diuresis functions | |
| CN101327200B (en) | Glycerol fruit sugar injection and preparation method thereof | |
| CN101966188A (en) | Amlodipine and candesartan-containing compound preparation for treating hypertension | |
| CN1060344C (en) | Shumaining preparation for curing ischemic angiocardiopathy or cerebrovascular disease | |
| KR20110131204A (en) | Plasma-adapted full electrolyte solution | |
| CN100388950C (en) | Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction | |
| CN101366968A (en) | Compound magnesium sulfate wet-dressing agent and preparation method thereof | |
| CN105147602B (en) | Formula mannitol injection liquid | |
| KR20030046445A (en) | A pharmaceutical composition for treating headache disease and process and uses thereof | |
| CN1244403A (en) | Preparation of isotomic Shengmei injecta | |
| CN1132584C (en) | Myopia treating eye drop | |
| CN103006622B (en) | New borneol use and lung cancer treatment drug composition | |
| CN102240261A (en) | Preparation method and medicinal purpose of glucomannan injection | |
| CN101269115B (en) | Cardiac and cerebral vascular disease treating medicament preparation and method for preparing the same | |
| CN102247338A (en) | Composite of glycerol and fructose | |
| CN105147600B (en) | A kind of compound formula mannitol injection liquid | |
| CN102657665B (en) | Compound dehydration and diuresis medicine composition | |
| CN1073600A (en) | The preparation method of the Chinese medicine preparation of treatment pseudomyopia | |
| CN107854664A (en) | A kind of inrigorating qi and promoting blood circulation silt Wine for reducing blood-pressure and preparation method thereof | |
| CN102228682A (en) | Medicinal composition for treating increased blood viscosity and blood supply insufficiency of brain tissues | |
| CN102048721A (en) | Injection preparation | |
| CN102440968A (en) | More stable desmopressin (DDAVP) polypeptide drug freeze-dried powder injection | |
| CN100998860A (en) | Troxerutin cerebroprotein hydrolysate sodium chloride injection liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090304 |